The N14 anti-afamin antibody Fab: a rare V
                    
                    1 CDR glycosylation, crystallographic re-sequencing, molecular plasticity and conservative
                    
                    enthusiastic modelling by Naschberger, Andreas et al.
research papers
Acta Cryst. (2016). D72, 1267–1280 http://dx.doi.org/10.1107/S205979831601723X 1267
Received 23 August 2016
Accepted 26 October 2016
Edited by R. J. Read, University of Cambridge,
England
Keywords: antibody fragment; flexibility;
variable-chain glycosylation; elbow angle;
precision; accuracy; solvent; non-apparent
isomorphism; solvent modelling.
PDB references: N14 Fab, crystal form I,
parsimonious model, 5l9d; crystal form I,
non-parsimonious model, 5l88; crystal form II,
5l7x; crystal form II: same as 5l7x, but
isomorphous setting indexed the same as 5l88
and 5l9d, 5lgh
Supporting information: this article has
supporting information at journals.iucr.org/d
The N14 anti-afamin antibody Fab: a rare VL1
CDR glycosylation, crystallographic re-sequencing,
molecular plasticity and conservative versus
enthusiastic modelling
Andreas Naschberger,a Barbara G. Fu¨rnrohr,a Tihana Lenac Rovis,b Suzana Malic,b
Klaus Scheffzek,a Hans Dieplingerc,d and Bernhard Ruppc,e*
aDivision of Biological Chemistry, Medical University of Innsbruck, Innrain 80, 6020 Innsbruck, Austria, bCenter for
Proteomics, University of Rijeka, B. Branchetta 20, 51000 Rijeka, Croatia, cDivision of Genetic Epidemiology,
Medical University of Innsbruck, Scho¨pfstrasse 41, 6020 Innsbruck, Austria, dVitateq Biotechnology GmbH, Innrain 66,
6020 Innsbruck, Austria, and eCVMO, k.-k. Hofkristallamt, 991 Audrey Place, Vista, CA 92084, USA. *Correspondence
e-mail: br@hofkristallamt.org
The monoclonal antibody N14 is used as a detection antibody in ELISA kits for
the human glycoprotein afamin, a member of the albumin family, which
has recently gained interest in the capture and stabilization of Wnt signalling
proteins, and for its role in metabolic syndrome and papillary thyroid carcinoma.
As a rare occurrence, the N14 Fab is N-glycosylated at Asn26L at the onset of
the VL1 antigen-binding loop, with the -1–6 core fucosylated complex glycan
facing out of the L1 complementarity-determining region. The crystal structures
of two non-apparent (pseudo) isomorphous crystals of the N14 Fab were
analyzed, which differ significantly in the elbow angles, thereby cautioning
against the overinterpretation of domain movements upon antigen binding. In
addition, the map quality at 1.9 A˚ resolution was sufficient to crystal-
lographically re-sequence the variable VL and VH domains and to detect
discrepancies in the hybridoma-derived sequence. Finally, a conservatively
refined parsimonious model is presented and its statistics are compared with
those from a less conservatively built model that has been modelled more
enthusiastically. Improvements to the PDB validation reports affecting ligands,
clashscore and buried surface calculations are suggested.
1. Introduction
1.1. The N14 monoclonal antibody: function and unique
features of its antibody fragment
Horseradish peroxidase-conjugated murine N14 IgG1
monoclonal antibody (mAB) is the detecting antibody in a
novel sandwich ELISA used for quantification of the human
glycoprotein afamin (Dieplinger et al., 2013; Dieplinger &
Dieplinger, 2015), a plasma vitamin E-binding glycoprotein of
the albumin gene family (Voegele et al., 2002). Afamin (AFM)
is a biomarker for metabolic syndrome and related cardio-
vascular disease as well as for ovarian cancer (Dieplinger et al.,
2009; Kronenberg et al., 2014; Seeber et al., 2014). Strong
interest in the AFM crystal structure results from the fact that
it seems to be, at least in vitro, a carrier for Wnt signalling
proteins (which are relevant in cell proliferation pathways),
which are otherwise very hard to solubilize and to purify
(Mihara et al., 2016). A potential role of afamin in the glucose
metabolism in papillary thyroid carcinoma has been reported
(Shen et al., 2016), and the N14 Fab (fragment, antigen
ISSN 2059-7983
binding) can serve as a scaffolding partner in AFM crystal-
lization. The N14 Fab displays a number of interesting struc-
tural features and its crystallization in two crystal forms with
non-apparent isomorphism also allows an extended analysis of
its structural flexibility and of the practice and effects of
extensive solvent model building.
1.2. Variable-domain IgG glycosylation
In addition to the frequent and in part conserved glycans of
antibody Fc (fragment, crystallizable) domains (Arnold et al.,
2007), glycosylations in the Fab regions of IgG antibodies
emerging primarily through somatic hypermutation have
gained increasing interest owing to their influence on IgG
function and immune regulation (van de Bovenkamp et al.,
2016). Genomic cDNA analysis reveals that about 15–25% of
Fabs are expected to be glycosylated overall (Anumula, 2012),
while only 9% of the variable regions are glycosylated based
on genomic cDNA analysis (Arnold et al., 2007). Glycosyl-
ations in the variable regions that are functionally relevant to
antigen (Ag) binding, for example, have been described at
Asn58H, Asn60H and Asn54H (Gala & Morrison, 2004). We
report crystallographic evidence for a rare glycosylation at
Asn26L at the onset of the variable light-chain L1 loop (VL1)
of the complementarity-determining region (CDR). Addi-
tional instances of variable-chain glycosylations of largely
unknown function detected in PDB models are compiled in
Supplementary Table S1 (see x3.3).
1.3. Crystallographic sequence verification
In order to successfully patent an antibody, various claims
are stated, with the most common being the sequence
(Holliday, 2009). With the decreasing cost of genomic
sequencing, the sequences of the VH and VL domains (or of
the set of six CDRs) started to dominate. To avoid competi-
tion, but also to prevent a threat from subsequently detected
deviations from the patented sequences, as was the case for
N14, patent claim rules usually permit changes in the CDR
sequences provided that 90 or 95% sequence identity is
retained (van der Hoff, 2014). One of the most important
items is to show that the claimed antibody is an alternative to
known antibodies. The existence of glycans within the variable
domains can then become a valuable piece of information in
supporting the claim. This is particularly the case owing to the
emerging importance of IgG Fab glycosylation in the immune
response (van de Bovenkamp et al., 2016).
The variable-region sequences of antibodies are most
frequently determined via RNA extraction from hybridoma
cells, reverse transcription, PCR and cDNA sequencing or via
mass-spectroscopic methods (see Zhang et al., 2014). Crys-
tallographic model building allows the sequence to be verified,
serving as a powerful alternative complementing these tech-
niques. Given a sufficiently high resolution (better than
2 A˚), the shape of the reconstructed electron density and the
chemical environment of side chains is expected to conform
to expectations. At sufficient map quality and resolution,
however, difference electron density and implausible stereo-
chemistry can indicate sequence discrepancies. We were able
to correct three sequence assignments, emphasizing the
benefit of careful inspection of difference maps, and affirming
the value of mAb variable-region sequence-propensity
compilations (Wu & Kabat, 1970; Martin, 1996).
1.4. One model might not be enough
The accuracy and precision of a molecular-structure model
represent two different qualities. The precision of individual
atomic coordinates, which for small-molecule structures is
directly obtainable from the covariance matrix (Sheldrick &
Schneider, 1997), is rarely computed in biomolecular refine-
ment (Tickle et al., 1998), largely because the inversion of the
Hessian second-derivative matrix is computationally too
expensive for highly multiparametric models (Tronrud, 2004).
Instead, estimated global measures such as the diffraction
precision index (DPI; Cruickshank, 1999) or measures derived
from maximum-likelihood (ML) estimates are substituted
(Vagin et al., 2004). Higher resolution in general provides a
larger amount of data and a correspondingly smaller variance
or higher precision of atomic coordinates upon refinement. In
contrast, the accuracy of macromolecular structures is not
clearly defined. While from a purely statistical viewpoint,
accuracy can be interpreted as the deviation of the expected
mean from an unknown true value (reflecting systematic
errors), macromolecular accuracy is a context-sensitive and
less well defined quality: in different environments, biological
macromolecules can crystallize in different crystal structures,
and altered packing contacts can capture different confor-
mational states. Various means of the visualization of such
conformational variance within a set of crystal structure
models have been suggested (see Kantardjieff et al., 2002). The
N14 Fab fragment provides an excellent example where
independent refinement of related Fab crystal structures leads
to models with significant conformational local and long-range
differences.
1.5. Conservative versus ‘enthusiastic’ model
As of yet, no real consensus exists in the structural biology
community as to up to which point weak electron density
should be modelled (Read & Kleywegt, 2009). Interpreting
weak density can often be ambiguous, but even at low
electron-density levels the interpretation of features based on
reasonable prior expectations such as known solvent compo-
sition or consensus about expected glycosylations can be
considered to be plausible. Overly enthusiastic interpretation,
however, often results in poor local real-space correlation,
excessive B factors and poor stereochemistry in the low-
density regions. As a result of the high B factors and/or partial
occupancies reducing the X-ray scattering contribution, only
small differences in global reciprocal-space statistics such as
R values appear. Statistical R-value-based Hamilton tests
(Hamilton, 1965) or likelihood or Bayes ratio tests (Kass &
Raftery, 1995) exist, but they are rarely used or, given the
small differences, do not always allow conclusive answers
about which model is better. We therefore elected to deposit
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both a conservative model and an ‘enthusiastic’ model of one
of the N14 Fab structures and suggest some practical points for
maintaining a parsimonious model without unduly restricting
experienced model building.
1.6. Fab-domain notation
The Kabat notation (Wu & Kabat, 1970) assigned by
AbNum from the KabatMan suite (Martin, 1996) is applied
throughout the manuscript for N14 residue numbering. The
two different chains of the antibody fragment are assigned as
L (light chain) and H (heavy chain). Each Fab chain consists
of a variable domain (VL and VH, respectively) harbouring
the six complementarity-determining regions (CDRs) and a
constant domain (CL and CH1, respectively); the domain
boundaries in Kabat notation are defined as VL  L107 < CL
and VH  H113 < CH1.
2. Experimental
2.1. Antibody and Fab preparation
Monoclonal antibodies against human afamin (N13 and
N14) were obtained with conventional hybridoma technology
(Ko¨hler & Milstein, 1975) by immunizing BALB/c mice with
purified human afamin dissolved in phosphate-buffered saline
solution (PBS) pH 7.4, as described in the supplemental
material of Dieplinger et al. (2013). Affinity-purified mouse
monoclonal IgG1 antibodies were
concentrated to 2 mg ml1 in PBS and
cleaved into Fab and Fc fragments
according to the protocol of Andrew &
Titus (2001). In brief, the antibodies
(2 mg ml1 in PBS) were dissolved in
equal volumes of freshly prepared 2
digestion buffer (0.035 M EDTA,
40 mM l-cysteine in PBS). Papain
(0.1 mg ml1) was also freshly prepared
in 2 digestion buffer and equal
volumes of antibody and papain were
mixed and incubated (37C, 2 h). The
reaction was stopped by adding iodo-
acetamide to a final concentration of
30 mM. Fab fragments were separated
from Fc fragments and remaining
uncleaved IgG on an A¨KTA FPLC
equipped with a Protein A column. The
Fab fragments from the flowthrough
were concentrated in PBS using centri-
fugal filter concentrators (molecular-
weight cutoff 10 kDa). Papain was
removed by size-exclusion chromato-
graphy (SEC) using a Superdex 200
10/300 column on an A¨KTApurifier 100
FPLC system (SEC buffer; 20 mM
HEPES pH 7.5, 150 mM NaCl). The Fab
solution was concentrated with a
centrifugal filter concentrator (Vivaspin
VS2021, 30 kDa cutoff) to a final concentration of 10 mg ml1.
The purity of the Fab was assessed by Coomassie-stained
SDS–PAGE analysis.
2.2. Sequence determination
The genomic sequence of the variable domains (VL and VH)
was determined by Oak Biosciences, Sunnyvale, California,
USA via RNA extraction from hybridoma cells, reverse
transcription, PCR and cDNA sequencing (http://
www.oakbiosciences.com/). Subsequent to the discovery of
three discrepancies between electron density and the assigned
genomic sequence, mass-spectrometric MALDI-TOF peptide
mapping of the N14 Fab at the Protein Micro-Analysis Facility,
Medical University of Innsbruck with 98% sequence coverage
of the VL chain and 80% coverage of the VH chain was
performed (see x3.2).
2.3. Crystallization
Crystals were grown at 291 K by sitting-drop vapour-
diffusion in 96-well plates (Swissci 30926) using 200 nl droplets
of antibody-fragment stock solution (10 mg ml1 SEC-purified
Fab fragment in 20 mM HEPES pH 7.5, 150 mM NaCl) mixed
with 200 nl crystallization cocktail in a robotic setup using a
Phoenix robot (Art Robbins Instruments, Sunnyvale, Cali-
fornia, USA) equipped with a single nanoneedle protein
dispenser (Krupka et al., 2002; Naschberger et al., 2015).
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Table 1
Crystallization, data collection and structure solution.
Crystal (PDB entries) N14C3 (5l9d, 5l88) N14A3 (5lgh, 5l7x)
Stock solution 10 mg ml1 N14 Fab in 20 mM HEPES pH 7.5, 150 mM NaCl
Crystallization conditions 30% PEG 1K, 0.2 M KF pH 5.8 30% PEG 1K, 0.2 M NH4F pH 5.5
ESRF ID29 wavelength (A˚) 1.0000 1.0000
ESRF data identification lat-N14_615_C3_w1_run1 lat-N14_615_A3_w1_run2
Space group (No.) P212121 (19) P212121 (19)
Unit-cell parameters† (A˚) a = 67.78 (9), b = 69.25 (8),
c = 87.80 (9)
a = 72.20 (3), b = 67.49 (5),
c = 88.94 (6) (5lgh)
Non-isomorphous setting N/A a = 67.49 (5), b = 72.20 (3),
c = 88.94 (6) (5l7x)
Unit-cell volume† (A˚3) 412113 (1401) 433385 (797)
Solvent fraction 0.439 0.466
VM (A˚
3 Da1) 2.19 2.31
Wilson B factor (A˚2) 36.6 40.0
Resolution‡ (A˚) 48.44–1.88 (1.95–1.88) 44.47–1.86 (1.93–1.86)
Completeness‡ (%) 99.4 (97.7) 98.6 (91.3)
Observed reflections‡ 154121 (10340) 142315 (9822)
Average redundancy‡ 4.5 (3.2) 3.9 (3.0)
hI/(I)i‡ 10.0 (1.4) 8.8 (1.0)
Rmeas‡§ (%) 9.1 (91.4) 9.5 (114.3)
Rmerge‡} (%) 7.6 (80.4) 7.4 (93.4)
CC1/2‡†† (%) 99.8 (68.8) 99.8 (46.6)
BALBES results
Q-score 0.814 0.815
Rfree 0.297 0.298
R 0.337 0.339
Rfree 0.152 0.170
† Values in parentheses are estimated standard uncertainties of the last significant digit(s). ‡ Values in parentheses are
for the highest resolution shell. § Rmeas =
P
hklfNðhklÞ=½NðhklÞ  1g1=2
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where
Ii(hkl) is the ith of N(hkl) observations of reflection hkl and hI(hkl)i is the weighted average intensity for all observations
of reflection hkl without symmetry merging. } Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is
the ith observation of reflection hkl and hI(hkl)i is the weighted average intensity for all symmetry-merged (unique)
observations of reflection hkl. †† CC1/2 is Pearson’s correlation coefficient between two randomly assigned data sets
each derived by averaging half of the observations for a given reflection.
Block-shaped crystals with sharp edges (0.15  0.15 
0.3 mm) grew within a day without optimization from the
Wizard PEG Ion 1 screen (Rigaku Reagents) in conditions A3
[N14A3; 30% polyethylene glycol mean molecular weight
1 kDa (PEG 1K) and 200 mM ammonium fluoride pH 5.5] and
C3 (N14C3; 30% PEG 1K, 200 mM potassium fluoride pH
5.8).
2.4. Data collection
Crystals were manually harvested using suitably sized
MiTeGen cryo-loops and cryo-meshes mounted on bar-coded
SPINE standard bases, and were flash-cooled without addi-
tional cryoprotection. The pins were placed in SPINE pucks
and transferred in dry shipping dewars to beamline ID29 at
the ESRF (de Sanctis et al., 2012) for robotic crystal mounting.
Diffraction data were collected at 100 K in single-wavelength
mode at 1.0000 A˚ (12.398 keV) using a Dectris PILATUS 6M
detector in fine-slicing mode from
automatically pre-screened crys-
tals using the mxCuBE beamline-
control software (Gabadinho et
al., 2010). Data were processed by
the EDNA automated data-
processing pipeline (Monaco et
al., 2013) employing XDS and
XSCALE (Kabsch, 2010),
POINTLESS, AIMLESS and
CTRUNCATE from the CCP4
program suite (Winn et al., 2011)
and phenix.xtriage from the
PHENIX suite (Adams et al.,
2011). To exclude any effects of
possible isomorphism between
the two data sets biasing Rfree, the
cross-validation flags from the
N14A3 data (1.86 A˚ resolution)
were transferred to N14C3
(1.88 A˚ resolution). Conservative
CC1/2 cutoffs of 0.69 and 0.47,
respectively, were selected for the
last resolution shells (Karplus &
Diederichs, 2012; Diederichs &
Karplus, 2013); the remaining
data statistics are listed in Table 1.
2.5. Structure determination
2.5.1. Automated molecular
replacement and ARP/wARP
model building. The merged and
unique data set of structure
factors together with the separate
light-chain (L) and heavy-chain
(H) sequences of murine Fab
12E8 (Trakhanov et al., 1999)
were submitted to CCP4 Online
(http://www.ccp4.ac.uk/ccp4online) for processing with the
BALBES automated structure-solution pipeline (Long et al.,
2008). In both cases the best solution was obtained with an
assembly of chains 1IL1(A)+1IL1(B) (Berry et al., 2001). The
molecular-replacement model was then automatically
submitted to ARP/wARP 7.5 (Langer et al., 2008) and the
resulting models were manually rebuilt with Coot (Emsley et
al., 2010) and refined with REFMAC5 (Murshudov et al., 2011)
from the CCP4 suite v.6.5 (Winn et al., 2011) using the CCP4i
graphical interface (Potterton et al., 2003).
2.5.2. Manual model building and refinement. Repeated
cycles of manual rebuilding in real space assigning the
commercially determined VL and VH domain sequences and
the germline sequences of the murine BALB/c constant
chains, followed by restrained reciprocal-space refinement
with REFMAC (Murshudov et al., 2011) using the default
flat masked solvent model, led to final models of good
stereochemical quality after constrained group occupancy
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Table 2
Refinement, validation and analysis of the deposited models.
The table contains statistics of interest for model comparison in xx3.2–3.4. The PDB headers include the full
information.
Model N14C3, conservative N14C3, optimistic N14A3
Refinement
PDB entry 5l9d 5l88 5l7x (5lgh)
Rfree (5% set) 0.215 0.211 0.228
Rwork 0.176 0.170 0.190
R 0.039 0.041 0.038
TLS groups 4 (VH, VL + glycan,
CH1, CL)
4 (VH, VL + glycan,
CH1, CL)
4 (VH, VL + glycan,
CH1, CL)
No. of atoms
Protein 3280 3300 3224
‘Ligand’ 97 189 64
Waters 221 252 223
All refined non-H 3598 3741 3511
hBi (A˚2)
Protein atoms 33.5 35.6 39.0
‘Ligand’ atoms 61.5 74.4 59.2
Waters 40.0 41.6 41.5
All refined non-H atoms 34.7 38.0 39.5
Refined occupancy groups 12 13 4
Glycans Asn26L-NAG Asn26L-NAG-FUC Asn26L-NAG
PEG fragments 7 14 5
Missing residues 6 3 16
Coordinate errors (A˚)
Free 0.139 0.140 0.139
A 0.119 0.120 0.141
Cruickshank DPI 0.154 0.156 0.154
Fo versus Fc correlation 0.967 0.970 0.968
Fo versus Fc correlation, free 0.956 0.956 0.955
R.m.s.d., bond lengths (A˚) 0.009 0.009 0.011
R.m.s.d., angles () 1.36 1.37 1.50
Geometry
Elbow angle () 139 139 147
Clashes, true, reported 4 of 10 5 of 11 3 of 3
Ramachandran†
Total 431 436 412
Allowed 7 8 6
Outliers 0 0 0
Real-space R outliers, RSRZ > 2 8 9 10
Side-chain rotamer outliers 6 9 14
Buried contact surface, reported, L+H‡ (A˚2) 6350, 1834 9640, 1854 5250, 1700
LLDF ‘ligand’ outliers 5 of 9 10 of 17 5 of 6
refinement of alternate conformations (Table 2). Inspection of
difference density maps in N14C3 as well as N14A3 revealed
three sequence discrepancies in the VH and VL domains (x2.2,
Fig. 1).
After initial automated weight selection, the REFMAC
Hessian matrix ratio weight was manually optimized to 0.05 by
LLfree minimization (Tickle, 2007) to convergence after the
B-factor restraint weights were set to empirically determined
plausible values (Tronrud, 1996). A simple Bayes ratio test
based on LLfree of the isotropic model without TLS (serving
as a null hypothesis) and with conservative TLS refinement for
separate VL (including the glycan), VH, CL and CH1 domains
(which also appeared plausible by molecular-dynamics TLS
analysis; Painter & Merritt, 2006) did favour the TLS model in
the range between ‘positive’ and ‘strongly’ [2ln(K) = 7.2; Kass
& Raftery, 1995].
2.5.3. Missing regions of the N14 models. As commonly
observed in Fab crystal structures, several loops at the term-
inal end of the CH1 domain are disordered and are probably
present in multiple conformations. Residues in the H127–
H133 region in N14C3 had weak and discontinuous electron
density, which could not be reliably modelled with a single
plausible geometry, and these residues were omitted from the
models. Despite the same nominal resolution, the loop regions
H127–H133, H155–H163 and H182–H193 as well as the
C-terminal residues of both chains are poorly defined in the
N14A3 model. Continuous stretches of unidentified branched
density in N14A3 which probably originate from missing loop
residues could not be modelled. Such density was kept empty
and was not filled with water or PEG fragments.
2.5.4. S—S bonds. The variable-region S—S bonds between
H22 and H92 and between L23 and L88 were refined in a
single conformation in both N14C3 and N14A3. In N14C3 the
constant-region H140–H195 and L134–L194 S—S links were
modelled as dual conformers forming two independent S—S
links. Additional difference density in both models suggested
some radiation damage (Garman, 2010) at the L134–L194
cysteine link, but no plausible model beyond the occupancy
group-refined split Cys–Cys link conformers in N14C3 could
be refined.
2.5.5. Glycosylations. Asparagine L26, located at the
beginning of hypervariable region L1, is glycosylated. A
corresponding N-linked N-acetylglucosamine (NAG), an
-1–6-linked fucose (FUC) and a -1–4-linked NAG, pointing
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Figure 1
Sequence corrections to the N14 model. The top row shows the originally assigned sequences (Met4L, Thr8L and Pro84L) and the row below the
corrected side chains (Leu4L, Pro8L and the split Ser84H in two conformations). The ball-and-stick models are displayed in 2mFo  DFc electron
density displayed at 1 (blue grid) and mFo DFc difference density (2.8; green and red grid for positive and negative difference density, respectively)
after refinement of the original N14C3 model (Met4L, Thr8L and Pro84H) with REFMAC (Murshudov et al., 2011) and are rendered in Coot (Emsley et
al., 2010). Note how the unusual non-Pro cis-peptide indicated by the red plane indicator reverts to a common pre-Pro cis conformation (green) and how
the incorrectly sequenced ProH84 causes a clash (red spikes) with, and displaces, the adjacent water atom, which is also consistent with the difference
density. The atom contacts were calculated with the MolProbity suite (Chen et al., 2010).
out of the antigen-binding region, could be placed into weak
electron density in both structures (Fig. 2a). The modelling of
the two branch saccharides (both omitted in the conserva-
tively refined deposited model) is ambiguous (RSCC < 0.7)
but is compatible with known Fab glycosylation patterns.
2.5.6. Solvent. Water molecules were placed individually
only into spherical positive difference density of >4.0 if
reasonable contacts to protein or other solvent moieties were
present. A few waters were group-refined with correlated
partial side-chain occupancies. In N14C3, an initially built
water molecule with sixfold coordination and positive differ-
ence density despite threefold lower B factors compared with
the surrounding protein residues was replaced by K+, a
component of the crystallization cocktail. After completion of
model refinement, positive OMIT difference density at the
presumed K+ site peaked at 16. The K+ cation mediates a
crystal contact between Asp207H and the symmetry-related
Ser71H and Asp55H, located in the H2 CDR (Fig. 2b).
Isoelectric Cl as a stock component (x2.1) was deemed to be
less plausible because the site is highly negatively charged.
Consistent with the absence of K+ from the cocktail compo-
nents, the corresponding site in N14A3 is less defined and was
modelled with a water molecule. Given a somewhat lower B
factor for this water than the average neighbour B factor, a
mixture of water with additional unknown metal ions and/or
ammonium ions from the cocktail cannot be excluded. Biva-
lent cations such as Ca2+ and Mg2+ are less likely owing to their
significantly shorter coordination distances. The entire contact
region in N14A3 is less ordered than in N14C3, with some
weak positive difference density fragments remaining in the
solvent.
Numerous stretches of unbranched continuous (difference)
electron density were interpreted as ordered fragments of
polyethylene glycol [PEG; HO(CH2CH2O)nH] from the
crystallization cocktail. A number of remaining positive
difference density fragments in the disordered terminal
regions, in the vicinity of the unmodelled flexible loops and in
disconnected density in the solvent regions could not be
plausibly modelled.
2.5.7. Validation. Refinement parameters and restraint
weights are listed in Table 2 and (redundantly) in the PDB
header, and validation reports are available from the PDB.
The top and only serious close contacts reported are not valid
because MolProbity (Davis et al., 2007; Chen et al., 2010) as
implemented by the PDB does not recognize partial corre-
lated occupancies constrained to 1.0 in the absence of
ALTLOC identifiers. The sole Ramachandran outlier reported
by Coot, Ser51L in both N14C3 and N14A3, as well as its
neighbouring residues, has an excellent electron-density fit
(RSCC > 0.9) and the backbone geometry must therefore be
considered as supported by evidence. Ser51L is located in a
conserved -turn and is frequently observed in a high-energy
conformation (Stanfield et al., 2006). RAMPAGE (Lovell et
al., 2003) and the PDB validation reported this residue in an
allowed region. The single K+ ion in N14C3 was validated and
cross-checked using CheckMyMetal (Zheng et al., 2014). The
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Figure 2
(a) Asn26L, located at the onset of L1, points out of the antigen-binding region into solvent. Shown is the first N-linked -N-acetylglucosamine (NAG),
the -1–6-linked fucose and the first -1–4-linked NAG of the extended glycan branch. 2mFo  DFc density is displayed at 0.8. In the deposited
conservative N14 model, only the Asn-linked NAG has been retained. (b) The K+-binding site linking Asp207H (ball-and-stick representation) and the
symmetry-related Ser71H and Asp55H (purple sticks) is shown together with coordinated water molecules (purple balls). Density levels are 1.3 (blue)
and 5 (magenta, around the K+ cation). See x3.5 for a discussion of glycan modelling.
conformations of the refined glycan anomers were validated
using Privateer-validate (Agirre et al., 2015) and agreed with
expectations. Elbow angles were calculated with the RBOW
Fab elbow-angle web service (Stanfield et al., 2006). Addi-
tional validation criteria relevant to the discussion of model
differences are provided in Table 2.
2.5.8. Modelling differences. The ‘enthusiastically’ built
model of N14C3 was obtained by successively adding model
features to the conservative N14C3 starting model. During
these steps, TLS parameters were kept constant and no
restraint weight optimization was conducted. After the final
additions, TLS parameters were again refined, with the matrix
weight remaining at 0.05. Details of and the motivation for the
extension of the model are provided in x3.5 ff.
3. Results and discussion
3.1. Unit-cell metric
The relation between the two crystal structures N14A3 and
N14C3 is different from what the lattice metric suggests at a
first glance. When the unit-cell parameters and reflection
indices are ordered by the convention1 a < b < c, the models
are not related by expected crystallographic transformations.
The cell has expanded (about 5% in volume) so that the new a
in N14A3 is now longer than b. To bring the models into an
isomorphous setting, the reflections of the original N14A3
a < b < c cell needed to be re-indexed as k, h, l, and the
model needed to be transformed with the Cartesian trans-
formation (x, y, z) = (y + 1/4a, x + 1/4b, z + 1/4c), with a > b <
c for the new cell. The relation between these two cells is best
described as non-apparent isomorphism.2 We therefore
deposited two models of N14A3, one in the setting conforming
to the a < b < c convention (PDB entry 5l7x) and one in the
swapped cell setting (PDB entry 5lgh) so that the models can
directly be displayed within their properly related unit cells.
All TLS records and anisotropy tensors have been converted
to the new setting.
3.2. Crystallographic sequence assignment
Three sequence discrepancies associated with a single
codon change were detected during model building, with the
side chains as identified by electron-density (mis)match being
highly plausible given the corresponding variable-region
sequence propensities (Martin, 1996; Johnson & Wu, 2000).
Residue Met4L (ATG) with a Kabat probability (KP) of 0.55
was unambiguously identified from electron density as Leu
(CTG) with a KP of 0.41; residue Thr8L (ACA) with a KP of
0.07 was unambiguously identified from electron density as
Pro (CCA) with a KP of 0.9. Residue Pro84H (ACT), with a
KP of 0.07, was identified from electron density with high
probability as a Ser in a split conformation (TCT), with a KP
of 0.39. Thr and Ala as alternative possibilities (KPs of 0.11
and 0.25) to Pro84H generated negative and positive differ-
ence density, respectively, and were deemed to be less
plausible (Fig. 1). Posterior mass-spectrometric MALDI-TOF
peptide mapping of the N14 Fab at the Protein Micro-Analysis
Facility, Innsbruck Medical University, with 98% sequence
coverage of the VL chain and 80% coverage of the VH chain,
identified all peptide fragments of N14 sequence as assigned
by electron-density inspection.
3.3. Differences between the two N14 crystal structures
The two structure models refined against data from non-
apparent isomorphous crystals obtained from the same batch
of protein stock under identical setup conditions with a
difference in the cation in the 200 mM cocktail additive (NH4F
versus KF) and associated pH changes diverge significantly in
tertiary structure (domain conformation) as well as in local
details. The N14C3 model with 5% lower unit-cell volume is of
higher overall quality, with a better map appearance and fewer
disordered regions than N14A3, despite comparable data-
quality statistics and resolution. The variable-domain back-
bones differ between the two structures slightly more than
with coordinate precision (VL 0.170 A˚,VH 0.191 A˚), while
the differences between the constant-domain backbones are
significantly larger (CL 0.336 A˚, CH1 0.348 A˚).
Detailed analysis of the intermolecular contacts using PISA
(Krissinel & Henrick, 2007) reveals that the K+ metal-binding
site exhibits a high complexation significance score (CSS),
indicating that the formation of this intermolecular interface
involving six residues is likely to be a prominent factor in the
tighter packing of the N14C3 crystal form. Transition-metal
ions in particular are frequently included in crystallization
cocktails as intermolecular contact-promoting additives
(McPherson, 1982; Trakhanov et al., 1998).
3.3.1. Elbow angles. The elbow angles of the two N14 Fab
models differ significantly, by 8, with the more open N14A3
form packing less densely. Both elbow angles are close to the
mode of the rather broad elbow-angle distribution typical for
the -chain IgG antibodies (Stanfield et al., 2006). The wider
elbow angle in N14A3 increases the distance between the CL
and CH domains compared with N14C3 (Fig. 3), which is
consistent with the larger unit-cell volume and smaller buried
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Table 3
Sequences of the six hypervariable loops of the complementarity-
determining regions (CDRs) of the afamin-binding region depicted in
Fig. 2.
Highlights are explained in the remarks column.
CDR region Residues Remarks
L1 (L24–L34) TANSSVSSNYFH Asn26L glycosylated
Canonical L1 -ASSSVSS-
L2 (L50–L56) STSNLAS Ser51L in high-energy conformation
L3 (L89–L97) HQYHRSPPT
H1 (H31–H35) SYIIH
H2 (H50–H65) YINPYNDGSKYNEKFKG Asp55H in K+-mediated crystal
contact
H3 (H95–H102) NYWSDSLDY
1 This convention is in fact unfortunate, because it leads to proliferation of
different axis permutations of the same space group. In space group 18, P21212,
for example, a swap of a with c would require deposition in space group
P22121.
2 We thank Zbigniew Dauter, ANL for this suggestion.
L–H contact surface of the N14A3 versus N14C3 crystal form
(Table 2).
In antibody Fab fragment structure refinement, differences
in elbow angles have been observed even between different
NCS-related copies in the same crystal (Stanfield et al., 1990,
2006), sometimes with elbow-angle changes exceeding 20
(PDB entry 1jnh, 27 difference; PDB entry 1s78, 22 differ-
ence; PDB entry 1ots, 21 difference). Given that molecular-
dynamics simulations of Fab-domain movement predict hinge-
bending fluctuations with only 2–3 r.m.s.d. in elbow angle in
solution (Sotriffer et al., 2000), the significant differences in
elbow-angle change between the N14A3 and N14C3 Fab
models are almost certainly a consequence of the different
crystallization conditions. While the antibody community has
learned to exercise caution when assigning significance to
antibody-domain rearrangements, strong conclusions about
domain orientations from a single-crystal structure may be a
risky proposition if not supported by independent assessment
of the solution conformation or multiple crystal structures
(Kantardjieff et al., 2002).
3.4. Antigen-binding site and glycosylation
The antigen-binding site projects almost entirely into
intermolecular solvent, with exception of the loops affected
by a crystal contact (Table 3). The deep antigen-binding cleft
between the VL and VH chains is occupied by a PEG fragment
embedded in a water network in both structures. Interestingly,
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Figure 3
Overall structure of the N14 anti-afamin antibody Fab fragment. (a) provides an overview of the N14A3 and N14C3 structure models superimposed on
the VL and VH domains. The different domain orientation of the constant regions is distinctly recognizable, with the larger elbow angle of N14A3
pushing the CL and CH domains wider apart, which may be one contributing factor to the 5% larger unit-cell volume of N14A3. The backbone traces are
shown as tube models coloured from the N-terminus (dark blue) to the C-terminus (red), with the location of the K+-binding site in N14C3 indicated by a
red sphere and the Asn26L glycosylation shown as a ball-and-stick model. (b) Electrostatic surface presentation (blue, positive charge; red, negative
charge) of the antigen-binding region (including the glycan, bottom left). The deep cleft between the VL and VH chains in the centre of the solvent-
exposed CDR region contains a PEG fragment embedded in a discrete water network (not shown). The second PEG fragment to the right mediates a
crystal contact. The displayed PEG fragments are present in both structures. (c) Surface map of binding properties: white, neutral surface; green,
hydrophobic surface; red, hydrogen-bonding acceptor potential; blue, hydrogen-bond donor potential. In (b) and (c) the glycan branch can be seen
protruding at the bottom left. Surface calculations and figure rendering by MolSoft ICM Browser Pro (Abagyan et al., 1994).
the glycosylation of Asn26L was observed (but was not further
expanded on) in an early milestone paper on mAB–antigen
peptide binding (Stanfield et al., 1990), with the site sequence
Asn26L-Gln27L-Thr27(A)L in an extended L1 CDR loop.
The Asn26L-Ser27L-Ser27(A)L sequence is the only
N-glycosylation site present in N14, and the prior probability
of observing the N-glycosylation consensus site sequence
Asn26L-Xxx27L-(Ser,Thr)27(A)L in a IgG1- mouse Fab is
quite low. Under the assumption of independence, the prior
probability based on Kabat propensities that a glycosylation
at position 26L occurs is P(glyc|26) = P(Asn|26) 
P(Ser,Thr|27A) = 0.009  (0.906 + 0.016) = 0.008; that is, about
1 in 100 mouse IgG1- Fab models with an insertion at posi-
tion 27(A) are expected to present this feature at site 26L. In
IgG1 Fabs with no 27L insertions, the corresponding prob-
ability is about 0.2%. Exposed glycans on IgG variable loops
tend to be complex and fully sialylated (Arnold et al., 2007).
The N14 L1 loop harbouring the N-glycosylation site
reveals almost an identical conformation to the ‘canonical
structure 1’ defined by Al-Lazikani et al. (1997), with the
exception of a peptide-bond flip at position Ser29L-Ser30L,
distant from Asn26L (Fig. 4a). A comparison between the
N-linked NAG glycan in PDB entry 1igf (where it could be
modelled in only one of the two NCS-related copies of the
unbound Fab fragment) and PDB entry 2igf (Fab bound with
Ag peptide) with the N14 conformation shows that while the
glycan does not seem to directly participate in peptide antigen
binding in PDB entry 2igf (Stanfield et al., 1990), the glycan
conformation is clearly affected by the packing of neigh-
bouring molecules, while the canonical CDR conformation is
maintained (Fig. 4b). Given that Asn26L is located at the
onset of hypervariable region L1 but pointing out from the
antigen-binding region, with little effect on the canonical L1
conformation, crystallographic evidence for a functional role
of the glycosylation may become available based on an AFM–
N14 complex crystal structure.
A simple text search of the PDB for antibody models
containing N-glycans identified five different IgG Fabs with VL
chain glycosylations [sites Asn22, 25, 26(2) and 72] and eight
instances with VH glycosylations (31, 52, 55, 57, 72, 73, 88, 96),
most of them containing only one or two modelled NAG
saccharides. A spreadsheet containing these instances (among
almost 200 search results with NAG moieties in other parts
of the model or complex) is deposited as Supplementary
Table S1.
3.5. Examining the trade-off between parsimony and
interpretative freedom
The steady improvement in structural model-validation
tools and the flagging of questionable models by the
community have led to increasing scrutiny of structure models.
Better structure models will improve the quality of the
research that is based on them, and enable more reliable meta
analysis and data mining of structure repositories (Dauter et
al., 2014). As a consequence of the trend towards improved
validation, almost all journals now realise the importance of
providing at least PDB validation reports to reviewers (see
Fink, 2016). Examining these reports can certainly prevent
grossly flawed models (which have previously escaped detec-
tion) entering the literature and becoming persistent in the
PDB (Rupp et al., 2016). However, the sole reliance on PDB
validation reports is not always sufficient to judge the validity
of claims, because the desire to provide simple metrics for
structure quality does not do justice to the complex task of
local model evaluation. Inspection of electron density is de
facto necessary for the full analysis and review of a structure
model. In addition, given the difficult mandate of the PDB
Validation Task Force (Read et al., 2011) to cover almost every
conceivable aspect of model validation, constant improvement
of the reports to eliminate errors and ambiguities, or to
reconsider metrics that cannot be applied to each and every
situation, are desirable.
A particularly intense feature of the validation reports are
the outlier reports, which are highlighted to draw the attention
of the depositor (or the ire of the reviewer). To explore the
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Figure 4
L1 CDR and glycan-binding site. (a) Main-chain superposition of N14 L1
CDR (yellow sticks) with the ‘canonical conformation structure 1’ (green
sticks; PDB entry 2fbj; Al-Lazikani et al., 1997). The glycosylation at
Asn26L located at the onset of the hypervariable region has little effect
on the canonical L1 conformation. (b) The glycan fragments in N14
(yellow sticks) and PDB entry 2igf (green sticks; Stanfield et al., 1990)
cannot possibly assume the same conformation despite a very similar loop
arrangement around Asn26L, because a symmetry-related molecule in
N14 (thin blue sticks) would interfere with the 2igf glycan conformation
in the case of N14. This figure was displayed and rendered with Coot
(Emsley et al., 2010).
ability of a reasonably experienced crystallographer and the
restraint necessary to produce a reasonably ‘clean’ PDB
validation report, we refined and deposited the N14C3 model
optimistically (meaning that we extended our interpretative
freedom to lower density levels while at the same time not
introducing obviously conjectural or wrong model features)
and with more parsimonious restraints, attempting to obtain a
validation report with a reasonably achievable minimum of
outliers. Examining these models might help aspiring model
builders to develop their own level of comfort for the in-
evitable compromise between reflective restraint and exces-
sive modelling enthusiasm.
3.5.1. The degree of surprise. Outliers are not necessarily
or always errors. They are expected to occur with a defined
frequency given by the amount of deviation of their respective
statistic from the sample mean or their deviation from an
empirical distribution. An intuitive way to look at them is to
judge them by how much they surprise us. Surprise is directly
related to informational entropy (Stone, 2015) and is a
powerful aid in judging the relevance of an outlier. A bond-
length outlier with a 5 deviation (RMSZ = 5, with an
expected frequency of occurrence of 1/150 000) does
surprise us and is, pending further investigation, very probably
an error. Whether a Ramachandran outlier surprises us
depends on conditioning information: without supporting
electron density it is likely to be a simple modelling error and
our surprise is modest, while supporting clear electron density
turns it from an outlier into an interesting feature worthy of
further contemplation.
3.6. Remarks on modelling practice
3.6.1. Backbone and close contacts. Given the repre-
sentative resolution of 1.9 A˚ (the PDB mean is around 2.2 A˚),
the models were not allowed to have unsupported Rama-
chandran outliers and only few close contacts (clashes;
Table 2) with a deviation of less than 0.6 A˚. Large deviations
from prior expectations in general either need correspond-
ingly strong evidence to be considered plausible, or most likely
are real errors that should be corrected, irrespective of any
allowances for interpretative freedom. The true clashscore for
all models is 1 (less than 1 in 1000 contacts). All Asn, Gln and
His side-chain flips proposed by MolProbity were also exam-
ined at this stage. Except for one ambiguous suggestion
involving a symmetry-related molecule in PDB entry 5l7x, all
Asn, Gln and His side-chain orientations could already be
assigned correctly during model building based on forming the
most plausible hydrogen-bond networks.
It is important to realise that the ’ and  backbone torsion
angles are normally not restrained in reciprocal-space refine-
ment and provide valuable geometric cross-validation. With
the protein backbone being one continuous chain and the
bond lengths and bond angles highly restrained, the only
option that the refinement program has to reduce scattering
contributions from the model in places where the data do not
justify this is to increase the B factors and/or to move the
atoms to places where they are less compromising in the
overall refinement target. The unrestrained backbone torsion
angles allow and absorb such movements and the resulting
outliers indicate that the model is not plausible in its current
conformation. While correcting the model to energetically
favourable backbone torsion angles in real space is reasonable,
restraining the backbone torsion in reciprocal-space refine-
ment is permissible only in rare circumstances. Low resolution
in general provides additional opportunities for modelling
errors and risky interpretation. The 2008 and 2011 CCP4
Study Weekend proceedings compiled in the February 2009
and April 2012 issues of Acta Crystallographica Section D
contain key references on refinement and validation of low-
resolution crystal structures.
The PDB validation report employs RAMPAGE (Lovell et
al., 2003), with more permissible allowed backbone torsion-
angle regions than the more restrictive values of Kleywegt &
Jones (1996) that are actually listed in the PDB file header
under REMARK 500.
3.6.2. Water. Water molecules were manually placed with
environmental restraints in mind. Irrespective of the absolute
density level, the density needed to be reasonably spherical
and plausible contacts to protein or neighbouring solvent
molecules had to be present. Placing waters, particularly early
on, into continuous blobs of significant density that are
obviously not just water does slightly improve the global
refinement statistics, but carries the penalty of obscuring the
shape of the surrounding difference density. This difference
density generally improves in shape as the refinement
progresses, and a more cognizant decision as to the nature of
the unknown moiety might then be made.
3.6.3. Disordered or missing model parts. Crystallo-
graphers tend to take personal affront when parts of a struc-
ture cannot be modelled because no supporting density exists.
In most circumstances (aside from proteolytic cleavages and
related instances) one is reasonably sure that the absent part
does exist, but its location is not defined. Although this is
normal. as many solution structures have demonstrated, it irks
the eager model builder, and some model is built, absent of
convincing density. Such enthusiasm bears two consequences.
Punishment is generally promptly delivered in the form of
poor local real-space statistics, combined with implausible
geometry, and the futile circle of rebuilding and obtaining
frustrating results is repeated ad tedium.
Secondly, placing a model in a specific conformation (or
two) when a whole ensemble of models might be equally
plausible can create a problem for unsuspecting users.
Although the resulting high B factors make localized electron
density disappear in agreement with reality, the atom records
in the PDB, and thus the balls and sticks in graphical repre-
sentations, firmly remain. Zero occupancies assigned to
questionable atoms are an equally imperfect remedy, if not
recognized by the user. An ensemble model with its multiple
chains occupied in accordance with their prior stereochemical
probabilities and given local environment restraints would
probably come closest to reality. Such composite models and
the means and ways of their representations (Koradi et al.,
1996) are a matter of fact in NMR structure studies and have
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been applied to macromolecules (Kantardjieff et al., 2002).
Four residues in the disordered CH1 domain (A129H, A130H,
Q131H and T132H) and two terminal residues (D1L and
C215H), as well as one ambiguous split side chain, are not
included in the conservative model, while the optimistic model
lacks only A130H and Q131H and D1L (see also Table 2).
3.6.4. Glycans. In many cases, N-linked glycan decorations
are only partly visible, with their electron density deteriorating
towards the solvent-exposed branch. Low-level density indi-
cates that a chain of covalently linked sugars is
present, but likely in multiple and dynamically
changing conformations. Placing a model there
on one hand does make it clear that something
has to be there, meaning that this region is
almost certainly excluded from access by other
parts of the molecule or by its complex part-
ners. This ‘excluded volume’ is de facto valu-
able information, for example in complex
modelling, but one single specific model does
not reflect the real situation. The punishment
for placing in part justified but ambiguous
models is again poor density fit, possibly
geometry violations, and a high, yellow-
highlighted LLDF because the glycans are
considered ‘ligands’. The arguable compromise
we selected is to show the actual density and a
possible but not unique model in Figs. 2 and 3,
demonstrating that something has to be there,
but depositing in the conservative model only
the positional and conformationally certain
Asn-linked NAG and omitting the second
NAG also in the enthusiastic model. While
simple omission is the easiest way to keep the
PDB report ‘clean’, one has to realise that such
a practice does not do justice to reality. How to
adequately present such situations of ‘known
absences’ remains an open question.
3.6.5. PEG fragments. PEGs [polyethylene
glycol, polyethylene oxide, H(OCH2CH2)n-
OH] and their monomethyl ethers (PEG
MMEs) are the most frequently used precipi-
tants in crystallization trials (McPherson, 1976,
1985). Despite their apparent structural (but
certainly not chemical; see Ray & Puvathingal,
1985) simplicity, they are difficult to model
correctly: almost always only ambiguous frag-
ments are identifiable [even low-molecular-
weight PEG 400 has about nine (OCH2CH2)
oxyethylene repeats on average]. Only when
the hydrogen bonds to the environment are
well defined can a decision be made whether a
C atom or an O atom should be placed at a
given location (see PG4 H301 in Fig. 5). More
often than not, bad contacts rather than neat
hydrogen bonds indicate a less offending
register of O and C atoms in the PEG fragment
chains. In addition, the present practice of
assigning a specific chemical entity based on the modelled
fragment length and perceived terminal atom is unrealistic.
Table 4 lists the PDB identifiers of available PEG fragments of
1  n  14 as a (at present) useful reference during model
building. A more systematic family tree of PEG fragments
with consistent and easily extensible (restraint file) nomen-
clature would be desirable.
PEG chains also have a similar shape (but considerably
more conformational freedom) than peptide backbones.
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Figure 5
PEG fragments ranked by LLDF. The PEG fragments are labelled as numbered in PDB
entry 5l6d and are ranked by the LLDF (best to worst), which is the first item in the data
columns/row, followed by the real-space R value (RSR) and the real-space correlation
coefficient (RSCC) as listed in the validation report. Density levels are 1 for the 2mFo 
DFc map (blue grid, highlighted around the PEG fragments) except for PG4 H305, where
the contours of the blue map have been lowered to 0.70. Difference density is shown at
	3 levels. Red LLDF numbers correspond to yellow highlights in the validation report.
The reason for the scores is not always transparent, which emphasizes the need for
electron-density inspection for ligands and caution against simple acceptance (or
condemnation) based on the LLDF score. For example, in PEG H307 it is obvious that
the model is insufficient to explain the additional density (perhaps an alternate
conformation), while the very plausible hydrogen-bond network of PG4 H301 does not
prevent a highlighted (presumably bad) score. Note that in contrast to H301 the central
positive density peak in PE8 H302 could not be modelled with a water molecule because it
was impossible (or beyond our limit of tedium) to orient the PE8 in one unique
conformation where only O atoms would form a reasonable hydrogen-bond network to the
neighbouring molecules. Incorrect register of the O versus C atoms frequently causes
improper close contacts to neighbouring atoms. 2mFo–DFc density is displayed at 1.2.
Note also that the assumption that PEG fragment models must always end with a terminal
oxygen (–OH) at each end is an unrealistic expectation. This figure was displayed and
rendered with Coot (Emsley et al., 2010).
Before building multiple conformations or instances of PEGs
to model branched continuous density, plausible explanations
such as an ordered piece of an otherwise missing peptide loop
or terminus should be considered. Premature solvent place-
ment can also obscure the shape of difference density. An
additional seven PEG fragments have been added to the seven
PEG fragments of the conservative model, and only two
fragments (see Fig. 5), conserved between the structures,
passed the muster of the LLDF validation metric.
3.7. Lessons learned: less can be more, but is it more
accurate?
The comparison of the different models of the same crystal
structure refined with different modelling philosophies allows
some interesting and also concerning conclusions. A funda-
mental principle which we applied to all models is that no
obvious errors were accepted, and interpretative freedom was
limited to parts in weak or ambiguous density, including
solvent.
Statistics and parameters relevant to the comparison are
listed in Table 2. Firstly, the removal of protein features placed
in weak density, such as terminal residues or residues flanking
chain breaks or of PEG molecules in very low density, has a
limited effect on the reciprocal-space statistics: the optimistic
model has lower R values, with Bayes ratios indicating
‘somewhat to positively better’, while the R–Rfree gap perhaps
indicates marginally less overmodelling for the conservative
model. Consistent with this modest assessment is the effect of
the relative Rfree decrease: Rfree is lower by 1.9%, which is
comparable to the estimated precision (1.7%) of Rfree
(Tickle et al., 2000). Only small effects on global reciprocal
statistics are expected because the high B factors reduce the
already small scattering contribution of the few ambiguous
model parts even further. Small increases in real-space outliers
and side-chain torsion outliers are attributable to the presence
of more ambiguous protein residues in the less parsimonious
model. The conclusion here is that if the model is reasonable
to begin with, a few low-density residues more or less will not
significantly affect the overall model statistics, but their
inclusion or absence can affect the accuracy of the model in
practical terms. The value of whether a questionable residue
or decoration is modelled or not depends on the intended use
of the model: is it for example important to know that a certain
region is excluded from interactions or is perhaps not surface
accessible, or that a glycan is likely to cause steric hindrances?
The increase in modelled PEG fragments does have some
interesting consequences. Only few, even plausibly modelled,
fragments can satisfy the LLDF criteria. We are not convinced
that eliminating most PEGs to satisfy the PDB validation
report is meaningful, and we suggest that solvent entities and
flexible decorations such as glycans are not judged by the
justifiably stricter criteria for a bona fide bound ligand. A
rather concerning result is that the buried surface area
between the two protein chains as reported by the automated
use of PISA (Krissinel & Henrick, 2007) for the PDB file
annotation does correlate strongly with the number of
modelled PEG fragments (see the recommendations below).
The effective trade-off between the attempt to achieve
completeness of a structure model by including parts modelled
with low confidence, at the risk of introducing stereochemistry
violations, has also surfaced in a comparison of structural
genomics (SG) initiative models with non-SG models. The
largely automatically built SG models tend to be more
conservatively built, but less complete, than crystal structure
models deposited by the general structural biology community
(Read & Kleywegt, 2009).
3.7.1. Suggestions for improving PDB reports and structure
annotation. PDB validation reports are undoubtedly helpful
for detecting and correcting previously missed, late-stage
errors in models. In particular, correcting clashes (improbable
close contacts) and examining backbone angle and rotamer
outliers clearly improves the posterior probability of the
model, as such errors are frequently also shown by careful
difference density inspection (for model correction, lower
contours than the ‘default’ 3 difference density are often
informative). However, some legitimate modelling is also
flagged as errors. Given the fact that these reports are
increasingly issued as a basis for review, we hope that the
remaining issues that we have identified can be addressed.
(i) The concurrent use of backbone-angle analysis programs
with different boundaries delivers inconsistent results. The
actual PDB files still include outliers reported using the 1996
metrics (Kleywegt & Jones, 1996) in REMARK 500, while the
RAMPAGE (Lovell et al., 2003) results in the validation
report show no such outliers. This discrepancy is simply
confusing and reporting should be made consistent.
(ii) A series of erroneously reported serious clashes in PDB
entries 5l9d and 5l88 can be traced back to problems that
MolProbity (Chen et al., 2010) presently has in correctly
interpreting correlated group occupancies when one of the
members does not have an alternate conformation. This is the
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Table 4
List of PDB three-letter identifiers (PDB codes) for PEG and PEG MME
fragments with n  14.
Many additional and inconsistently named fragments of presumably the same
chemical entities exist, terminating with two C atoms (examples are 16P, 7PE,
AE4, AE3, P3G, PE4, PE5 and others).
No. of PEG
units (n)
PEG PDB ID
C2nOn+1H4n+2
HO(CH2-CH2-O)nH
PEG MME PDB ID
C2n+1On+1H4n+4
HO(CH2-CH2-O)nCH3
1 EDO MXE
2 PEG PG0
3 PGE TOE
4 PG4 ETE
5 1PE 1PG
6 P6G P15
7 P33 —
8 PE8 7PG
9 2PE —
10 XPE —
11 — —
12 12P —
13 33O —
14 PE3 —
case, for example, when a water molecule is present at occu-
pancy n and the conflicting conformation of a split residue is
occupied at 1  n. We also found a partially occupied Met
whose terminal –CH3 group apparently conflicted with a
neighbouring residue 3.3 A˚ away. In this instance, no H atoms
were calculated for one of the alternate conformations and
we have no explanation for the origin of this problem. The
corresponding REFMAC group occupancy keyword file is
supplied as Supporting Information.
(iii) Complex solvent components other than water are the
greatest obstacle to obtaining a clean PDB report. In view of
the reports of ligand models without density support, the well
intended LLDF quality metric makes sense in structure
models where a ligand is proposed to be tightly bound to a
molecule in a specific pose, serving to support some biological
hypothesis: a strong claim indeed requires a strong proof.
Solvent molecules are currently classified as ligands, and in the
case of conformationally promiscuous PEG fragments or
glycan decorations, the stringent LLDF criteria highlight as
suspect even models at defensible RSCCs of as high as 0.9
(Fig. 5). Eliminating such molecules from the model simply to
satisfy a presently too broadly applied stringent metric is not
necessarily the best option. The area occupied by glycans, for
example, is excluded from access, which is potentially useful
and valid information. Low-density and omit difference
density contours do carry some information in those instances.
How to model such entitles at the solvent boundary (see
Holton et al., 2014; Weichenberger et al., 2015), doing justice to
their ambiguity while not categorically condemning those
attempts at obtaining a more accurate model, has not yet been
resolved.
(iv) Table 2 reveals that while the solvent-accessible surface
area (reported automatically in the PDB file by PISA; Kris-
sinel & Henrick, 2007) between the Fab complex formed
between the L and H chains remains almost constant, the
buried surface area increases by nearly 50% when more PEG
molecules are added to the model. This is obviously an artefact
which cautions that these values as listed in the PDB file
greatly depend on the quality and extent of solvent modelling.
If such differences are possible even between different
instances of the same structure model, a comparison between
different structure models becomes completely dependent on
individual solvent modelling and corresponding caution in the
interpretation of the automatically created values as listed in
the PDB REMARK 350 header is advisable.
The origin of the discrepancies in the PISA calculation
seems to come from the very unfortunate diktat of the PDB to
override author assignment of solvent moieties such as PEGs
by changing the chain IDs to that of the nearest protein chain
and assigning the ‘ligand’ category to it. Without manually
turning off the perceived PEG ligands in PISA, the buried
surface area between chains thus becomes a function of the
extent of solvent modelling. While glycans are a bona fide
component of the macromolecule itself, the solvent molecules
originating from crystallization precipitants are decidedly not
and are highly variable depending on the environmental
context.
4. Concluding remarks
The two independently refined crystal structure models of the
N14 anti-afamin antibody Fab fragment crystallizing in two
crystal forms with non-apparent isomorphism allowed a
number of interesting observations. N14 serves as the detec-
tion antibody in afamin ELISAs (Dieplinger et al., 2013), and
its Fab antibody fragment can be used for crystallization
scaffolding experiments of the complex glycosylated human
plasma protein afamin, which is a promiscuous transporter of
hydrophobic molecules, including vitamin E (Voegele et al.,
2002). Afamin may also play a role in the Wnt signalling
pathway or serve as a chaperone enhancing the solubility of
Wnt proteins (Mihara et al., 2016) and has a potential role in
glucose metabolism in papillary thyroid carcinoma (Shen et al.,
2016).
Electron density at 1.9 A˚ resolution in combination with
prior expectations based on antibody sequence (Kabat)
variability was sufficient to detect three clear sequencing
discrepancies probably caused by single codon-read errors.
The VL and VH sequences were obtained from commercial
sequencing of the BALB/c hybridoma cell lines used for mAB
production, and verification by independent means such as
mass-spectrometric sequence mapping or high-resolution
crystallographic studies may be prudent.
The deposition of two different models, one conservatively
refined in an attempt to minimize outliers in the PDB vali-
dation reports and the other optimistically interpreted, show
that is not possible to satisfy PDB reports without losing some
valid information that could be relevant for users of the
model. It is important that reviewers are made aware of how
to interpret the reports in these contentious areas and that
ultimately only the inspection of electron density can provide
clarity about the validity of claims based on X-ray crystallo-
graphic studies. After all, the scientists must be the judges
of their hypotheses and not the (validation) statistician
(Edwards, 1992).
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